Janet H Ford

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 4

Top Topics

Patient Reported Outcomes

Temporal Lobe Epilepsy

Top Venues

Clinical drug investigation

This page only lists publications with an associated author ORCID identifier.

Publications

Richard B Lipton, Dawn C Buse, Claire H Sandoe, Janet H Ford, Austin L Hand, Jakub P Jedynak, Martha D Port, Holland C Detke
Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study. Headache (2023)
Stewart J Tepper, Jessica Ailani, Janet H Ford, Russell M Nichols, Lily Q Li, Phebe Kemmer, Austin L Hand, Antje Tockhorn-Heidenreich
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER). Clinical drug investigation 42 (3) (2022)
Rebecca M Speck, Ren Yu, Janet H Ford, David W Ayer, Rohit Bhandari, Kathleen W Wyrwich
Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine. Headache 61 (3) (2021)
Janet H Ford, Tobias Kurth, Amaal J Starling, David W Ayer, Linda A Wietecha, Martha D Port, Mallikarjuna Rettiganti, Dustin D Ruff
Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine. Headache 60 (10) (2021)